
BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma
Follows U.S. approval for relapsed or refractory marginal zone lymphoma in 2021 Third approved indication for BRUKINSA in Canada, following mantle cell lymphoma (MCL) and […]



